Development and validation of an improved liquid chromatography–mass spectrometry method for the determination of pemetrexed in human plasma

An improved liquid chromatography–mass spectrometry method for the determination of pemetrexed in human plasma was developed and validated using a simple quadrupole LC–MS and a new SPE cartridge (Plexa ® Bond Elut). The analysis was achieved with a C18 analytical column using a mobile phase consisti...

Full description

Saved in:
Bibliographic Details
Published in:Journal of chromatography. B, Analytical technologies in the biomedical and life sciences Analytical technologies in the biomedical and life sciences, 2009-08, Vol.877 (24), p.2451-2456
Main Authors: Bobin-Dubigeon, C., Amiand, M.B., Herrenknecht, C., Bard, J.M.
Format: Article
Language:English
Subjects:
Analysis
Analytical, structural and metabolic biochemistry
Antineoplastic Agents - blood
Biological and medical sciences
Chromatography, Liquid - methods
Drug Monitoring - methods
Fundamental and applied biological sciences. Psychology
General pharmacology
Glutamates - blood
Guanine - analogs & derivatives
Guanine - blood
Humans
Liquid chromatography/mass spectrometry
Mass Spectrometry - methods
Medical sciences
Pemetrexed
Pharmacokinetic studies
Pharmacology. Drug treatments
Plasma
Sensitivity and Specificity
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:An improved liquid chromatography–mass spectrometry method for the determination of pemetrexed in human plasma was developed and validated using a simple quadrupole LC–MS and a new SPE cartridge (Plexa ® Bond Elut). The analysis was achieved with a C18 analytical column using a mobile phase consisting of formic acid/acetonitrile and isocratic flow for 7 min. The linear ranges ( r 2 > 0.99) were found from 5 to 5000 ng/mL. The lower limit of detection was 2.5 ng/mL. Within-day and between-day precisions were less than 7.2% and inaccuracy did not exceed 2.8%. This new method is suitable to support pharmacokinetic studies and drug monitoring.
ISSN:1570-0232
1873-376X
DOI:10.1016/j.jchromb.2009.06.020